Synairgen’s inhalable drug fails study in hospitalised COVID patients

Feb 21 (Reuters) – Synairgen (SYNG.L) said on Monday its inhalable therapy failed an international late-stage trial testing the treatment in patients hospitalised with COVID-19, in a blow to the development of the British drugmaker’s key product.

SNG001, an inhalable formulation containing the broad-spectrum antiviral protein interferon beta, is also being tested in a late-stage COVID-19 trial…

Continue Reading

News Source:

Leave a comment

Your email address will not be published.